| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
GSK321 has IC50 values of 4.6 nM, 3.8 nM, and 2.9 nM for R132H, R132C, and R132G, respectively, indicating that it is strongly suppressive to mutant IDH1 enzyme [1]. H3K9me2 levels are dramatically decreased by GSK321 (0, 0.5, 5 μM; 48 hours) [1]. GSK321 inhibits the growth of primary IDH1 mutant AML cells and decreases intracellular 2-HG [1]. GSK321 has inhibitory effect towards mutant IDH1, surmounting the typical differentiation barriers of AML cells and promoting myeloid differentiation of IDH1 mutant cells to the extent of leukemic blasts and stem cell-like cells [1]. In IDH1 mutant AML cells, GSK321 results in genome-wide DNA cytosine hypomethylation [1].
|
|---|---|
| Cell Assay |
Western Blot analysis [1]
Cell Types: HT-1080 Cell Tested Concentrations: 0, 0.5, 5 μM Incubation Duration: 48 h Experimental Results: diminished histone H3K9 dimethylation (H3K9me2). Cell proliferation assay[1] Cell Types: IDH1 mutant AML cells Tested Concentrations: 3 μM Incubation Duration: 15 days Experimental Results: There was an initial significant increase in cell number (2-fold to 15-fold) in IDH1 mutant AML cells. Cell cycle analysis[1] Cell Types: IDH1 Mutant AML Cell Tested Concentrations: Incubation Duration: 7 Days Experimental Results: A reproducible and significant reduction in quiescent (G0) phase cells was observed in R132G IDH1 and R132C IDH1 AML cells. |
| References |
|
| Molecular Formula |
C28H28FN5O3
|
|---|---|
| Molecular Weight |
501.5520
|
| Exact Mass |
501.217
|
| CAS # |
1816331-63-1
|
| Related CAS # |
(S,R)-GSK321;1816272-18-0
|
| PubChem CID |
91864709
|
| Appearance |
Off-white to light brown solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
809
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
FC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C2=C(C(C(N([H])C3=C([H])C([H])=C([H])C([C@]([H])(C([H])([H])[H])O[H])=C3[H])=O)=N1)C([H])([H])N(C(C1=C([H])C([H])=C([H])N1[H])=O)C([H])([H])[C@@]2([H])C([H])([H])[H]
|
| InChi Key |
IVFDDVKCCBDPQZ-MSOLQXFVSA-N
|
| InChi Code |
InChI=1S/C28H28FN5O3/c1-17-14-33(28(37)24-7-4-12-30-24)16-23-25(27(36)31-22-6-3-5-20(13-22)18(2)35)32-34(26(17)23)15-19-8-10-21(29)11-9-19/h3-13,17-18,30,35H,14-16H2,1-2H3,(H,31,36)/t17-,18+/m1/s1
|
| Chemical Name |
(7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide
|
| Synonyms |
GSK-321.; GSK 321; GSK321
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~498.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9938 mL | 9.9691 mL | 19.9382 mL | |
| 5 mM | 0.3988 mL | 1.9938 mL | 3.9876 mL | |
| 10 mM | 0.1994 mL | 0.9969 mL | 1.9938 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
